Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplantation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Uhm, Jieun | - |
dc.date.accessioned | 2023-10-10T02:58:24Z | - |
dc.date.available | 2023-10-10T02:58:24Z | - |
dc.date.created | 2023-05-30 | - |
dc.date.issued | 2023-04 | - |
dc.identifier.issn | 2287-979X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/191980 | - |
dc.description.abstract | The treatment outcomes of chronic myeloid leukemia in chronic phase (CML-CP) have dramatically improved with comparable life-expectancy to average of general population in tyrosine kinase inhibitor (TKI) era. However, less than a half of patients who started with TKI can remain on frontline TKI. The reasons of switching TKI can be either intolerance or the lack of efficacy. Although a kinase domain (KD) mutation can guide to select salvage TKI from the point of view on the efficacy of TKIs, many factors need to be considered before choosing next-line TKI such as the high-risk features of CML, the adverse events with prior TKI, and the comorbidities of patients. The therapeutic options for CML-CP after failing frontline TKI due to treatment failure or suboptimal responses will be reviewed including allogeneic hematopoietic stem cell transplantation. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Korean Society of Hematology | - |
dc.title | Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplantation | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Uhm, Jieun | - |
dc.identifier.doi | 10.5045/br.2023.2023054 | - |
dc.identifier.scopusid | 2-s2.0-85159696186 | - |
dc.identifier.wosid | 001058076100015 | - |
dc.identifier.bibliographicCitation | Blood Research, v.58, pp.S109 - S113 | - |
dc.relation.isPartOf | Blood Research | - |
dc.citation.title | Blood Research | - |
dc.citation.volume | 58 | - |
dc.citation.startPage | S109 | - |
dc.citation.endPage | S113 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002952082 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | KINASE DOMAIN MUTATIONS | - |
dc.subject.keywordPlus | FOLLOW-UP | - |
dc.subject.keywordPlus | IMATINIB-RESISTANT | - |
dc.subject.keywordPlus | WORKING PARTY | - |
dc.subject.keywordPlus | DASATINIB | - |
dc.subject.keywordPlus | NILOTINIB | - |
dc.subject.keywordPlus | CML | - |
dc.subject.keywordPlus | INTERFERON | - |
dc.subject.keywordPlus | CYTARABINE | - |
dc.subject.keywordPlus | BOSUTINIB | - |
dc.subject.keywordAuthor | Chronic myeloid leukemia | - |
dc.subject.keywordAuthor | Tyrosine kinase inhibitors | - |
dc.subject.keywordAuthor | Ponatinib | - |
dc.subject.keywordAuthor | Asciminib | - |
dc.subject.keywordAuthor | Allogeneic hematopoietic stem cell transplantation | - |
dc.identifier.url | https://www.bloodresearch.or.kr/journal/view.html?doi=10.5045/br.2023.2023054 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.